10416 related articles for article (PubMed ID: 14619465)
1. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
2. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
[TBL] [Abstract][Full Text] [Related]
3. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
4. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
[TBL] [Abstract][Full Text] [Related]
5. Locoregional cellular immunotherapy for patients with advanced esophageal cancer.
Toh U; Yamana H; Sueyoshi S; Tanaka T; Niiya F; Katagiri K; Fujita H; Shirozou K; Itoh K
Clin Cancer Res; 2000 Dec; 6(12):4663-73. PubMed ID: 11156218
[TBL] [Abstract][Full Text] [Related]
6. [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer].
Toh U; Fujii T; Mishima M; Imaizumi T; Koga A; Yano S; Shirouzu K; Yahara T; Yamana H
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1931-3. PubMed ID: 18219856
[TBL] [Abstract][Full Text] [Related]
7. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
[TBL] [Abstract][Full Text] [Related]
9. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
Zanovello P; Rosato A; Bronte V; Cerundolo V; Collavo D
Ann Ist Super Sanita; 1991; 27(1):91-5. PubMed ID: 1958033
[TBL] [Abstract][Full Text] [Related]
11. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
[TBL] [Abstract][Full Text] [Related]
12. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
Adler A; Stein JA; Kedar E; Naor D; Weiss DW
J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
[TBL] [Abstract][Full Text] [Related]
14. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
15. Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer.
Toh U; Sudo T; Kido K; Matono S; Sasahara H; Mine T; Tanaka T; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Int J Clin Oncol; 2002 Dec; 7(6):372-5. PubMed ID: 12494255
[TBL] [Abstract][Full Text] [Related]
16. Autologous activated lymphocyte therapy in a community hospital.
Horváth J; Szabó-Szabari M; Sinkovics JG
Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
18. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy].
Mitachi Y; Murakawa Y; Okuno M; Kambe M; Kanamaru R; Takahasi H; Wakui A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):482-8. PubMed ID: 2138871
[TBL] [Abstract][Full Text] [Related]
19. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
20. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Kitsukawa K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
